Patents by Inventor Claude Quesnelle

Claude Quesnelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof
    Patent number: 8999918
    Abstract: Disclosed are compounds of Formula (I) and/or salts thereof: wherein R1 is —CH2CH2CF3; R2 is —CH2CH2CF3 or —CH2CH2CH2CF3; R3 is H, —CH3, or Rx; R4 is H or Ry; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer; or as prodrugs of such compounds.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: April 7, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, George V. DeLucca, Daniel O'Malley, Patrice Gill, Claude A. Quesnelle, Brian E. Fink, Yufen Zhao, Francis Y. Lee
  • BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS
    Publication number: 20140357605
    Abstract: Disclosed are compounds of Formula (I) or prodrugs thereof; wherein: R1 is —CH2CF3 or —CH2CH2CF3; R2 is —CH2CF3, —CH2CH2CF3, or —CH2CH2CH2CF3; R3 is H or —CH3; each Ra is independently F, Cl, —CN, —OCH3, and/or —NHCH2CH2OCH3; and z is zero, 1, or 2. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Application
    Filed: July 28, 2014
    Publication date: December 4, 2014
    Inventors: Ashvinikumar V. Gavai, Claude A. Quesnelle, Soong-Hoon Kim
  • CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS
    Publication number: 20140256700
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 26, 2014
    Publication date: September 11, 2014
    Inventors: Michael A. Poss, David R. Tortolani, Dharmpal S. Dodd, Christopher P. Mussari, John S. Tokarski, Ashvinikumar V. Gavai, Yufen Zhao, George V. Delucca, Daniel O'Malley, Derek J. Norris, Patrice Gill, Claude A. Quesnelle, Wen-Ching Han
  • Bisfluoroalkyl-1,4-benzodiazepinone compounds
    Patent number: 8822454
    Abstract: Disclosed are compounds of Formula (I) or prodrugs thereof; wherein: R1 is —CH2CF3 or —CH2CH2CF3; R2 is —CH2CF3, —CH2CH2CF3, or —CH2CH2CH2CF3; R3 is H or —CH3; each Ra is independently F, Cl, —CN, —OCH3, and/or —NHCH2CH2OCH3; and z is zero, 1, or 2. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: September 2, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Claude A. Quesnelle, Soong-Hoon Kim
  • BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS
    Publication number: 20140100365
    Abstract: Disclosed are compounds of Formula (I) or prodrugs thereof; wherein: R1 is —CH2CF3 or —CH2CH2CF3; R2 is —CH2CF3, —CH2CH2CF3, or —CH2CH2CH2CF3; R3 is H or —CH3; each Ra is independently F, Cl, —CN, —OCH3, and/or —NHCH2CH2OCH3; and z is zero, 1, or 2. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Application
    Filed: December 9, 2013
    Publication date: April 10, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ashvinikumar V. Gavai, Claude A. Quesnelle, Soong-Hoon Kim, Francis Y. Lee
  • BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF
    Publication number: 20140087992
    Abstract: Disclosed are compounds of Formula (I) and/or salts thereof: wherein R1 is —CH2CH2CF3; R2 is —CH2CH2CF3 or —CH2CH2CH2CF3; R3 is H, —CH3, or Rx; R4 is H or Ry; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer; or as prodrugs of such compounds.
    Type: Application
    Filed: September 20, 2013
    Publication date: March 27, 2014
    Inventors: Ashvinikumar V. Gavai, George V. DeLucca, Daniel O'Malley, Patrice Gill, Claude A. Quesnelle, Brian E. Fink, Yufen Zhao, Francis Y. Lee
  • Bisfluoroalkyl-1,4-benzodiazepinone compounds
    Patent number: 8629136
    Abstract: Disclosed are compounds of Formula (I) or prodrugs thereof; wherein: R1 is —CH2CF3 or —CH2CH2CF3; R2 is —CH2CF3, —CH2CH2CF3, or —CH2CH2CH2CF3; R3 is H or —CH3; each Ra is independently F, Cl, —CN, —OCH3, and/or —NHCH2CH2OCH3; and z is zero, 1, or 2. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: January 14, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Claude A. Quesnelle, Soong-Hoon Kim, Francis Y. Lee
  • BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS
    Publication number: 20120245151
    Abstract: Disclosed are compounds of Formula (I) or prodrugs thereof; wherein: R1 is —CH2CF3 or —CH2CH2CF3; R2 is —CH2CF3, —CH2CH2CF3, or —CH2CH2CH2CF3; R3 is H or —CH3; each Ra is independently F, Cl, —CN, —OCH3, and/or —NHCH2CH2OCH3; and z is zero, 1, or 2. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Application
    Filed: March 22, 2012
    Publication date: September 27, 2012
    Inventors: ASHVINIKUMAR V. GAVAI, CLAUDE A. QUESNELLE, SOONG-HOON KIM, FRANCIS Y. LEE
  • Thiazolyl compounds useful as kinase inhibitors
    Patent number: 8148400
    Abstract: The invention provides compounds of formula II: and pharmaceutically acceptable salts thereof. The formula II thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anne Marinier, Claude A. Quesnelle, Marco Dodier, Stephan Roy, Patrice Gill, Mark D. Wittman, David R. Langley
  • Aminopyrazole kinase inhibitors
    Patent number: 7851500
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: December 14, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Marco Dodier, Claude A. Quesnelle, Anne Marinier
  • THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20100048581
    Abstract: The invention provides compounds of formula I [INSERT CHEMICAL STRUCTURE HERE] (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: December 19, 2007
    Publication date: February 25, 2010
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Anne Marinier, Claude A. Quesnelle, Marco Dodier, Stephan Roy, Patrice Gill, Mark D. Wittman, David R. Langley
  • AMINOPYRAZOLE KINASE INHIBITORS
    Publication number: 20100022503
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: January 4, 2008
    Publication date: January 28, 2010
    Inventors: Marco Dodier, Claude A. Quesnelle, Anne Marinier
  • Imidazo-fused oxazolo [4,5-]pyridine and imidazo-fused thiazolo[4,5-]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 7456194
    Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: November 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric Dyckman, William J. Pitts, Makonen Belema, Patrice Gill, James Kempson, Yuping Qiu, Claude Quesnelle, Steven H. Spergel, F. Christopher Zusi
  • Imidazo-fused oxazolo[4,5-?]pyridine and imidazo-fused thiazolo[4,5-?]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 7176214
    Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: February 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: William J. Pitts, Makonen Belema, Patrice Gill, James Kempson, Yuping Qiu, Claude A. Quesnelle, Steven H. Spergel, Fred Christopher Zusi
  • Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    Publication number: 20060217412
    Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Application
    Filed: June 1, 2006
    Publication date: September 28, 2006
    Inventors: William Pitts, Makonen Belema, Patrice Gill, James Kempson, Yuping Qiu, Claude Quesnelle, Steven Spergel, Fred Zusi
  • Pyrimidine inhibitors of phosphodiesterase (PDE) 7
    Patent number: 7087614
    Abstract: Pyrimidine phosphodiesterase 7 (PDE 7) inhibitors of the following formula wherein R1, R2, Z, J and L are described herein, and analogs thereof are provided which are useful in treating T-cell mediated diseases.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: August 8, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Junqing Guo, Joseph Barbosa, William John Pitts, Marianne Carlsen, Claude Quesnelle, Marco Dodier
  • Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    Publication number: 20060106051
    Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Application
    Filed: November 10, 2005
    Publication date: May 18, 2006
    Inventors: Alaric Dyckman, William Pitts, Makonen Belema, Patrice Gill, James Kempson, Yuping Qiu, Claude Quesnelle, Steven Spergel, F. Zusi
  • Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    Publication number: 20050101626
    Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Application
    Filed: May 18, 2004
    Publication date: May 12, 2005
    Inventors: William Pitts, Makonen Belema, Patrice Gill, James Kempson, Yuping Qiu, Claude Quesnelle, Steven Spergel, Fred Zusi
  • Pyrimidine inhibitors of phosphodiesterase (PDE) 7
    Publication number: 20030162802
    Abstract: Pyrimidine phosphodiesterase 7 (PDE 7) inhibitors of the following formula 1
    Type: Application
    Filed: June 17, 2002
    Publication date: August 28, 2003
    Inventors: Junqing Guo, Joseph Barbosa, William John Pitts, Marianne Carlsen, Claude Quesnelle, Marco Dodier